CRITICAL PATH INSTITUTE
collaborate · innovate · accelerate

FOR IMMEDIATE RELEASE

Contact: Lisa Romero
                                   Communications & Development Manager
                                   520-547-3440
                                   lromero@c-path.org
                                   www.c-path.org

LEADING NEUROSCIENTIST JOINS CRITICAL PATH INSTITUTE
Marc Cantillon, MD, Hired as Executive Director, Coalition Against Major Diseases

Tucson, Arizona, November 18, 2010 – **Marc Cantillon, MD,** has joined Critical Path Institute (C-Path) as Executive Director of one of its major consortia, the Coalition Against Major Diseases (CAMD). Dr. Cantillon has a 15+ year background in government, academic and pharmaceutical industry translational research, drug development and clinical research. Dr. Cantillon earned his MD from the Karolinska Institute in Sweden. After postdoctoral training in internal medicine, neurology, psychiatry, and rehabilitation and a National Institutes of Health (NIH) Fellowship in Neuropsychopharmacology, he joined the intramural faculty at the NIH. He held faculty positions at Georgetown University in Washington D.C. and the University of Miami, founding a Neuropsychiatric service as part of a memory clinic, as well as teaching residents and Fellows. He was principal investigator on numerous clinical trials in Alzheimer's Parkinson's, and other neuropsychiatric disorders, including within the Alzheimer's Disease Cooperative Study (ADCS). He then moved to pharmaceutical clinical development in positions of increasing responsibility in AstraZeneca, Wyeth (Pfizer) and most recently Schering-Plough (Merck). Dr. Cantillon is board certified in psychiatry/geriatric psychiatry by the American Board of Psychiatry and Neurology.

While working as a scientist in the pharmaceutical industry, Dr. Cantillon helped develop multiple innovative drugs for psychosis, mood disorders, pain, chemotherapy, post-operative nausea, and neurodegenerative diseases such as Parkinson's, Multiple Sclerosis and Alzheimer's. He has been an active industry scientific member of the following consortia, focused on improving treatment development methodology and better options for patients and caregivers: Alzheimer's Disease Neuroimaging Initiative, American College of Neuropsychopharmacology (ACNP), The Michael J. Fox Foundation, local and national Alzheimer's Associations, Critical Path Institute's Patient Reported Outcomes (PRO) Consortium and CAMD itself. He has contributed to the Pharmaceutical Research and Manufacturer of America (PhRMA) and European Federation of

Pharmaceutical Industries and Associations (EFPIA) at the European Medicines Agency (EMA) on guideline recommendations for treatment of Parkinson's and Alzheimer's diseases.

CAMD is helping the U.S. Food and Drug Administration (FDA) and the pharmaceutical industry identify and adopt innovative testing methods that lead to increased efficiency, safety, and speed in developing new therapies for major diseases. CAMD is a global collaboration of 200+ scientists from biopharmaceutical companies, academic institutions, government regulatory agencies, six patient advocacy organizations, and other key stakeholders.

"C-Path is extremely fortunate that Dr. Cantillon now brings his expertise in neuropsychiatry and drug development to lead CAMD as it takes on Alzheimer's and Parkinson's diseases," said Dr. Ray Woosley, President and CEO of C-Path. "One of the greatest challenges facing biomedical sciences in the 21st century is the development of fundamentally better treatments for these and other neurodegenerative diseases.

In Dr. Cantillon's new role with CAMD, he is responsible for leading the C-Path team that provides overall leadership and project management for the consortia. Dr. Cantillon will help CAMD scientists define priority disease areas and will form and manage working groups for each of these diseases, as well as action plans to address CAMD's overall strategic goals.

According to Dr. Cantillon, **"**Neurodegenerative diseases have remained beyond the reach of drug discovery and continue to result in added costs for treatment, chronic suffering, and the loss of lives. Data sharing is the central focus of several CAMD projects designed to develop tools that identify patients who might develop brain diseases, i.e., *before symptoms are apparent*. Our goal is to develop tools to prevent or slow these diseases so patients can maintain independence and quality of life."

_____

About Critical Path Institute (C-Path): An independent, non-profit organization established in 2005, C-Path is committed to transformational improvement of the drug development process. An international leader in forming collaborations around this mission, C-Path has brought recognition to Arizona through first of its kind global programs and partnerships which currently include over 750 scientists from international government regulatory agencies, academia, patient advocacy organizations, and thirty major pharmaceutical companies. C-Path is headquartered in Tucson, Arizona, with offices in Phoenix, Arizona, and Rockville, Maryland. For more information, visit www.c-path.org.

About CAMD: CAMD members fully share pre-competitive data and knowledge that will more efficiently and safely speed development of new therapies and preventions for Alzheimer's, Parkinson's, Huntington's, and other debilitating neuro-degenerative diseases. CAMD's overall objective is to help scientists identify clinical and laboratory characteristics of patients who are pre-symptomatic and most likely to benefit from new therapies.

In June 2010, CAMD launched a first-ever database of combined clinical trials to be openly shared by pharmaceutical companies and made available to qualified researchers around the world. Currently, the database contains information from approximately 4,000 Alzheimer's subjects from eleven industry-sponsored clinical trials and provides the platform for researchers to design more efficient clinical trials of new treatments. This will allow the industry to more rapidly identify potential therapies that have a positive effect on disease progression, as well as to stop work earlier on therapies that show no benefit. For more information on CAMD and the database, visit http://www.c-path.org/CAMD.cfm.

###